Arcutis Biotherapeutics (ARQT) is currently in a buy zone and looks to stretch a winning streak, with the IBD 50 stocks To Watch pick for Thursday, and skin-disorders treatment specialist, appearing set to broaden its product reach and bolster sales.
The biotech stock on Thursday was on course for a fourth consecutive gain
During the run, Arcutis secured regulatory acceptance… Related news Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating 3/25/2026 A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving technical performance. 3/25/2026 A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving